AU2022361421A1 - Flavonoid derivatives with gabaa receptor activity and methods of use - Google Patents
Flavonoid derivatives with gabaa receptor activity and methods of use Download PDFInfo
- Publication number
- AU2022361421A1 AU2022361421A1 AU2022361421A AU2022361421A AU2022361421A1 AU 2022361421 A1 AU2022361421 A1 AU 2022361421A1 AU 2022361421 A AU2022361421 A AU 2022361421A AU 2022361421 A AU2022361421 A AU 2022361421A AU 2022361421 A1 AU2022361421 A1 AU 2022361421A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- bond
- group
- groups
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253341P | 2021-10-07 | 2021-10-07 | |
| US63/253,341 | 2021-10-07 | ||
| PCT/US2022/045904 WO2023059802A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022361421A1 true AU2022361421A1 (en) | 2024-05-09 |
Family
ID=85803715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022361421A Pending AU2022361421A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240398821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538721A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118354770A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022361421A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233822A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023059802A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604831B2 (ja) * | 1975-10-20 | 1985-02-06 | 中外製薬株式会社 | 4(3h)−キナゾリノン誘導体の製法 |
| US5258478A (en) * | 1992-04-27 | 1993-11-02 | Florida State University | Low self-absorbing, intrinsically scintillating polymers |
| GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
| RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2808680A1 (en) * | 2010-08-24 | 2012-03-01 | The Regents Of The University Of California | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
| CN106478525A (zh) * | 2015-08-28 | 2017-03-08 | 南京理工大学 | 一种合成喹唑酮的方法 |
| CN109879820B (zh) * | 2019-02-26 | 2022-07-19 | 扬州大学 | 一种喹唑啉酮杂环化合物的合成方法 |
-
2022
- 2022-10-06 CN CN202280080629.4A patent/CN118354770A/zh active Pending
- 2022-10-06 JP JP2024521052A patent/JP2024538721A/ja active Pending
- 2022-10-06 AU AU2022361421A patent/AU2022361421A1/en active Pending
- 2022-10-06 CA CA3233822A patent/CA3233822A1/en active Pending
- 2022-10-06 WO PCT/US2022/045904 patent/WO2023059802A1/en not_active Ceased
- 2022-10-06 EP EP22879291.7A patent/EP4412605A4/en active Pending
- 2022-10-06 US US18/699,103 patent/US20240398821A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024538721A (ja) | 2024-10-23 |
| EP4412605A4 (en) | 2025-07-30 |
| CN118354770A (zh) | 2024-07-16 |
| CA3233822A1 (en) | 2023-04-13 |
| US20240398821A1 (en) | 2024-12-05 |
| EP4412605A1 (en) | 2024-08-14 |
| WO2023059802A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230365542A1 (en) | Selective Agonists of 5-HT2A Receptor and Methods of Use | |
| EP3445749B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| CN102958937B (zh) | 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物 | |
| JP2014055156A (ja) | Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 | |
| WO2002013812A1 (en) | Methods for treating inflammatory diseases | |
| KR20210031931A (ko) | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 | |
| WO2024010585A1 (en) | Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use | |
| AU2005237607B2 (en) | Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases | |
| WO2022061196A1 (en) | Novel formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (mdma) | |
| JP3939369B2 (ja) | β3 −アドレナリン作動薬として作用する{(7S)−7−[(2R)−2−(3−クロロフェニル)−2−ヒドロキシエチルアミノ]−5,6,7,8−テトラヒドロナフタレン−2−イルオキシ)酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬 | |
| US20240398821A1 (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| US20220315624A1 (en) | Thiostrepton analogs and methods of making and using same | |
| JP2024170613A (ja) | Sstr4アゴニスト及びその塩の調製のための方法並びに使用のための用量レジメン | |
| AU2003267557B2 (en) | Treatment of dyskinesia | |
| US20220267308A1 (en) | Modulators of Excitatory Amino Acid Transporters and Methods Using Same | |
| WO2025217596A1 (en) | Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof | |
| WO2023006993A1 (en) | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome | |
| WO2025217249A1 (en) | Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment | |
| EP2964331B1 (en) | Pentacyclic pyridoindolo[b,e]azepine derivatives and uses thereof | |
| EP4642451A2 (en) | N-myristoyltransferase inhibitors and methods of use | |
| HK40115276A (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| AU2006291059A1 (en) | Salicylate and gentisate salts of a piperazine compound | |
| EP4554595A2 (en) | Galpha12 inhibitors and methods using same | |
| US20230399303A1 (en) | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | |
| KR20250129797A (ko) | 글루코오스 수치를 조절하기 위한 조성물 및 방법 |